Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
Amicus Therapeutics reports 2024 revenue of $528M, a 32% increase, with positive 2025 growth projections for key therapies. 2024 total revenue reached $528.5 million, marking a significant year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback